NCT07017725 - A Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 3, 2025

Primary Completion Date

June 1, 2026

Study Completion Date

December 30, 2026

Conditions

Chronic Immune Thrombocytopenia

Interventions

DRUG

CID-103

Strength:20 mg/mL. Route of administration: IV infusion. Treatment duration: QW for 6 weeks, then at the same dose Q2W up to Week 12. If treatment continues after Week 12, dosing will occur monthly for up to a maximum treatment duration of six months.

Trial Locations (6)

50000

NOT_YET_RECRUITING

Qilu Hospital of Shandong University, Jinan

300000

RECRUITING

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin

330000

NOT_YET_RECRUITING

The First Affiliated Hospital of Nanchang University, Nanchang

450000

NOT_YET_RECRUITING

Henan Cancer Hospital, Zhengzhou

650000

NOT_YET_RECRUITING

The Second Affiliated Hospital of Kunming Medical University, Kunming

063000

RECRUITING

North China University of Science and Technology Affiliated Hospital, Tangshan